- Histologically confirmed adenocarcinoma of the colon or rectum.
- T3 or T4 adenocarcinoma or node positive colorectal tumours.
- Appropriate staging investigations of the primary tumour, either endorectal
ultrasound or pelvic MRI.
- Male or female aged 18 to 70.
- Have a performance status ECOG of 0 or 1.
- Have a life expectancy greater than 6 months.
- Adequate organ function and coagulation parameters as measured by: WBC > 4000/mm3,
PLT > 100000/mm3, Hb > 10g/dL, ALT < 1.5X ULN, AST < 1.5X ULN, bilirubin < 1.5mg/dL
Serum creatinine < 1.8mg/dL.
- Patient consent.
- Known to have clinical or radiological evidence of distant metastases.
- Evidence of intestinal obstruction (except for those after enterostomy).
- Patients with a past history of colorectal surgery (except for enterostomy),
chemtherapy, radiation, biotherapy or targeted therapy.
- Pregnant woman OR women of childbearing potential with a positive pregnancy test at
baseline or lactating.
- Sexually active males and females (of childbearing potential) unwilling to practice
contraception during the study.
- Patients with a past or current history (within last 5 years) of other malignancies,
except for the indication under this study and curatively treated basal and squamous
skin cancer or in-situ cancer of the cervix.
- Patients with mental disorder unable to complete the informed consent.
- Uncontrolled hypertension.
- Clinically significant (i.e. active) cardiovascular disease for example:
cerebrovascular accidents (<=6 months), myocardial infarction (<= 6 months), unstable
angina, New York Heart Association (NYHA) grade II or greater congestive heart failure,
serious cardiac arrhythmia requiring medication.
- Moderate or serious proteinuria.
- Known hypersensitivity against experimental drugs.